BerandaNB11 • FRA
add
Vaxart Inc
Tutup sebelumnya
€0,44
Rentang hari
€0,41 - €0,41
Rentang tahun
€0,41 - €1,32
Kapitalisasi pasar
124,25 jt USD
Volume Rata-Rata
4,16 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 4,93 jt | 134,79% |
Biaya operasional | 4,34 jt | -11,77% |
Laba bersih | -14,08 jt | 19,08% |
Margin laba bersih | -285,42 | 65,54% |
Penghasilan per saham | -0,06 | 45,45% |
EBITDA | -12,25 jt | 22,25% |
Tarif pajak efektif | -0,13% | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 58,71 jt | 195,97% |
Total aset | 166,67 jt | 57,77% |
Total liabilitas | 98,23 jt | 187,89% |
Total ekuitas | 68,44 jt | — |
Saham yang beredar | 227,48 jt | — |
Harga terhadap nilai buku | 1,46 | — |
Tingkat pengembalian aset | -25,81% | — |
Tingkat pengembalian modal | -37,18% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -14,08 jt | 19,08% |
Kas dari operasi | -4,20 jt | 72,00% |
Kas dari investasi | -17,04 jt | -442,84% |
Kas dari pembiayaan | -10,00 rb | -25,00% |
Perubahan kas bersih | -21,25 jt | -111,67% |
Arus kas bebas | 60,98 jt | 243,95% |
Tentang
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly-owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Didirikan
Mar 2004
Kantor pusat
Situs
Karyawan
109